For instance, access to life-saving anti-HER2 therapy requires reliable HER2 testing, yet surveys indicate that in some low- and middle-income countries a significant fraction of breast cancer patients do not receive HER2 testing due to lack of pathology infrastructure and cost constraints [219]. This evidence concerns the gene ERBB2 and breast cancer.